CG Oncology, Inc. Common stock
CGON
$66.25
+8.46%
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing its lead product candidate, cretostimogene grenadenorepvec, a targeted oncolytic immunotherapy for bladder cancer patients. The company operates as a pure-play clinical-stage biotech, distinct in its focus on a single, intravesically delivered agent currently in pivotal Phase 3 trials for high-risk and intermediate-risk non-muscle invasive bladder cancer (NMIBC). The current investor narrative is dominated by anticipation of clinical trial readouts and potential regulatory filings for its lead asset, with recent price volatility reflecting binary sentiment swings typical of late-stage biotech stocks ahead of key catalysts.…
CGON
CG Oncology, Inc. Common stock
$66.25
Investment Opinion: Should I buy CGON Today?
Hold. CGON represents a high-risk, high-reward speculative bet on a single late-stage clinical asset, suitable only for investors with a high risk tolerance and a long-term horizon who can withstand near-total capital loss. The unanimous 'Buy' analyst consensus reflects optimism on the drug's potential, but specific price targets are unavailable to quantify the implied upside, leaving valuation entirely speculative.
The supporting evidence for a Hold rating is the juxtaposition of strong institutional belief (6 out of 6 analysts bullish) and a pristine balance sheet (current ratio of 24.6, D/E of 0.009) against catastrophically weak fundamentals. The company is valued at a PS ratio of 794x despite generating negligible and inconsistent revenue, has an operating margin of -47.2%, and burns over $130M in cash annually. The stock has already surged 132% over the past year, suggesting much of the near-term optimism may be priced in, while recent momentum has turned negative (-3.5% over 1 month).
The thesis would upgrade to a Buy only upon positive Phase 3 data readouts that de-risk the clinical pathway and provide a tangible path to the projected $1.5B+ in revenue. It would downgrade to a Sell on negative clinical data, a significant dilution event at a lower share price, or a sustained break below key technical support near $54. Relative to any traditional financial metric, CGON is profoundly overvalued, but within the context of late-stage biotech, its valuation reflects the speculative premium for a potential blockbuster drug, making it fairly valued only for those betting on flawless trial success.
Sign up to view all
CGON 12-Month Price Forecast
CGON is a pure-play, binary-event biotech stock where the 12-month outlook is dominated by the pending Phase 3 data readouts for its lead asset. The current neutral stance reflects the extreme asymmetry of the investment: the bull case offers multi-bagger potential, but the bear case implies a loss of over 60% of capital. The strong balance sheet provides runway but does not mitigate clinical risk. The stance would upgrade to bullish only upon confirmation of positive clinical data that validates the blockbuster sales projections. It would turn bearish on any sign of clinical faltering, increased dilution, or a breakdown below the $50 support level, which would signal a loss of market confidence ahead of the catalyst.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on CG Oncology, Inc. Common stock's 12-month outlook, with a consensus price target around $86.12 and implied upside of +30.0% versus the current price.
Average Target
$86.12
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$53 - $86
Analyst target range
Analyst coverage for CGON is limited but uniformly bullish among the six firms providing estimates. The consensus recommendation is a 'Buy' or equivalent, as evidenced by recent actions from firms like HC Wainwright, Truist Securities, and RBC Capital all maintaining positive ratings. The average revenue estimate for the forward period is $1.507 billion, with a wide range from $952.1 million to $3.408 billion, but specific price targets are not provided in the data, preventing a calculation of implied upside or downside to the current stock price. The extremely wide range in revenue estimates, spanning a difference of over $2.4 billion between the low and high, signals very high uncertainty and a lack of consensus on the commercial potential and timing of cretostimogene's launch, which is typical for a late-stage biotech without an approved product; the consistent 'Buy' ratings from all covering analysts, however, indicate strong institutional belief in the underlying clinical data and regulatory pathway.
Bulls vs Bears: CGON Investment Factors
The bull case for CGON rests almost entirely on the successful development and approval of its single lead drug candidate, cretostimogene, supported by a strong balance sheet and unanimous analyst optimism. The bear case is grounded in an extreme valuation that discounts perfect success, coupled with no current profits, high cash burn, and total dependence on a single clinical asset. Currently, the bearish evidence holds stronger weight due to the objective, unsustainable valuation multiples (PS of 794x) and the absence of any fundamental financial metrics to support the current price. The single most important tension in the investment debate is the binary outcome of the ongoing Phase 3 trials: positive data could justify the premium and unlock multi-billion dollar revenue potential, while any setback could collapse the valuation thesis entirely, given the complete lack of a financial safety net.
Bullish
- Strong Balance Sheet & Low Debt: The company has a robust current ratio of 24.63 and a negligible debt-to-equity ratio of 0.0093, providing significant financial runway to fund its pivotal Phase 3 trials without the immediate risk of a dilutive debt raise. This liquidity is critical for a pre-revenue biotech, evidenced by the recent $99.066 million equity issuance in Q4 2025 to support operations.
- Unanimous Analyst Bullish Sentiment: All six covering analysts have a 'Buy' or equivalent rating on the stock, reflecting strong institutional conviction in the clinical and commercial potential of its lead candidate, cretostimogene. This consensus, despite a wide revenue estimate range ($952M-$3.4B), signals a high degree of confidence in the drug's eventual approval and market success.
- Significant Long-Term Price Appreciation: The stock has delivered a 132.42% return over the past year, significantly outperforming the S&P 500's 24.99% gain. This dramatic price action reflects a major re-rating based on positive clinical trial progression and the company's advancement to late-stage development.
- Large Addressable Market & Pivotal Trials: CGON's lead asset targets a high-unmet-need bladder cancer market, with two Phase 3 trials underway. The average analyst revenue estimate of $1.507 billion for the forward period underscores the substantial commercial potential being priced into the stock, contingent on successful trial outcomes.
Bearish
- Extreme Valuation Based on Zero Sales: The stock trades at an astronomical Price-to-Sales (PS) ratio of 794.47x and an EV/Sales of 837.74x, pricing in near-flawless execution and blockbuster sales. This valuation leaves no margin for error, as any clinical or commercial setback could trigger a severe de-rating.
- Deeply Unprofitable with High Cash Burn: The company is pre-revenue and burning cash aggressively, with a Q4 2025 net loss of $41.3M, an operating margin of -47.22%, and TTM free cash flow of -$132.5M. This unsustainable burn rate necessitates future dilutive equity offerings, as seen with the recent stock issuance, to fund operations.
- Revenue Volatility & Negative Gross Margin: Quarterly revenue is negligible and highly volatile, ranging from $0 to $2.3M, and the latest quarter posted a gross margin of -25.5%. This confirms the company lacks a commercial product and its current 'revenue' is not from core operations, highlighting the binary, all-or-nothing nature of the investment.
- Recent Momentum Reversal & High Volatility: Despite strong 1-year performance, the stock is down 3.51% over the past month and 6.15% over the past three months, underperforming the market and showing a divergence from its longer-term uptrend. While its beta is low (0.308), this masks the high, news-driven volatility intrinsic to its clinical-stage status, with a 52-week range from $23.65 to $75.50.
CGON Technical Analysis
The stock is in a volatile, long-term uptrend but has recently corrected from its highs. Over the past year, the price has surged 132.42%, yet as of the latest close of $61.08, it is trading approximately 19% below its 52-week high of $75.50 and 158% above its 52-week low of $23.65, indicating it has retreated from peak momentum levels but remains significantly elevated from its base. Recent momentum has turned negative, with the stock down 3.51% over the past month and 6.15% over the past three months, diverging sharply from the strong yearly gain and signaling a potential consolidation or profit-taking phase after the prior rally. Key technical levels are clearly defined by the 52-week range, with immediate resistance near the $75.50 high and support at the $23.65 low; a sustained break below recent lows near $54 could signal deeper correction, while a reclaim of the $75 level would confirm resumption of the uptrend. The stock's beta of 0.308 suggests it has been significantly less volatile than the broader market over the measured period, which is unusual for a clinical-stage biotech and may reflect its specific news-driven price action rather than systematic market moves.
Beta
0.31
0.31x market volatility
Max Drawdown
-27.4%
Largest decline past year
52-Week Range
$24-$76
Price range past year
Annual Return
+159.3%
Cumulative gain past year
| Period | CGON Return | S&P 500 |
|---|---|---|
| 1m | +3.1% | -0.2% |
| 3m | +3.8% | +14.0% |
| 6m | +65.0% | +7.8% |
| 1y | +159.3% | +25.3% |
| ytd | +58.5% | +9.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CGON Fundamental Analysis
The company is in a pre-revenue, clinical development stage with minimal and inconsistent revenue streams. For Q4 2025, revenue was $2.322 million, representing a modest 4.09% year-over-year growth, but quarterly revenues have been volatile, ranging from $0 to $2.322 million over the past two years, indicating the business model is not yet commercial and growth metrics are not currently meaningful. CGON is deeply unprofitable, with a Q4 2025 net loss of $41.309 million and a gross margin of -25.5%, reflecting the cost-intensive nature of clinical trials without a commercial product; losses have generally widened quarter-over-quarter (e.g., from a $31.798 million loss in Q4 2024), and operating margins remain deeply negative at -47.22%. The balance sheet shows a strong liquidity position with a current ratio of 24.63 and minimal debt (debt-to-equity of 0.0093), but it is burning cash aggressively with free cash flow of -$132.48 million TTM and an operating cash flow of -$36.216 million in the latest quarter, indicating dependence on equity financing (evidenced by common stock issuances like the $99.066 million in Q4 2025) to fund operations and advance its clinical programs.
Quarterly Revenue
$2322000.0B
2025-12
Revenue YoY Growth
+4.09%
YoY Comparison
Gross Margin
-0.25%
Latest Quarter
Free Cash Flow
$-132480000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CGON Overvalued?
Given the company's negative net income of -$41.309 million and negative EBITDA of -$40.46 million for the latest quarter, the primary valuation metric selected is the Price-to-Sales (PS) ratio, as profitability-based multiples are not applicable. The trailing PS ratio is an extraordinarily high 794.47x, while the forward-looking metric is not directly available, but the massive premium reflects the market's valuation of future potential sales rather than current financials. Comparing to industry averages is challenging with such an elevated PS ratio, but it unequivocally trades at a massive premium to any profitable sector, justified only by the binary, high-risk/high-reward nature of a late-stage biotech with a pivotal asset; the EV/Sales ratio of 837.74x further confirms the extreme premium embedded in the enterprise value. Historically, the stock's own PS ratio has fluctuated wildly, from 1,382.27x at the end of Q4 2025 to as high as 58,914.78x in Q3 2024; the current 794.47x, while still astronomically high, is below its recent peak, suggesting some cooling of speculative fervor but remaining firmly in a zone pricing in near-perfect clinical and commercial success.
PE
-20.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -74x~-12x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-20.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and fundamental. CGON is a pre-revenue company with no commercial product, evidenced by volatile quarterly revenue that peaked at just $2.3M and a deeply negative gross margin of -25.5% in its latest quarter. It is burning cash at an alarming rate, with TTM free cash flow of -$132.5M and a Q4 2025 net loss of $41.3M, which necessitates continued equity dilution to fund its pivotal trials, as seen with the $99M stock issuance in Q4 2025. The entire investment thesis is concentrated in a single, unapproved drug candidate, creating a classic 'binary event' risk profile where company value is contingent on clinical trial success.
Market & Competitive Risks center on valuation compression and competitive disruption. The stock trades at a PS ratio of 794.47x, an extreme premium that leaves it vulnerable to a sharp de-rating if growth expectations are not met or if market sentiment towards high-risk biotech sours. While its beta of 0.308 suggests low correlation with the broader market, this is misleading; the stock's true volatility is event-driven (clinical data, FDA decisions). Furthermore, the bladder cancer treatment landscape is competitive, and any negative data readout or superior competitor result could rapidly erode CGON's projected market share and valuation.
The Worst-Case Scenario involves the lead candidate, cretostimogene, failing to meet its primary endpoints in ongoing Phase 3 trials. This would likely result in a collapse of the commercial narrative, analyst downgrades, and a rapid exodus of speculative capital. The realistic downside could see the stock re-testing its 52-week low of $23.65, representing a potential loss of approximately -61% from the current price of $61.08. A more moderate adverse scenario, involving trial delays or mixed data, could see a drawdown towards the -27.41% maximum drawdown level observed recently, implying a drop to roughly $44-45 per share.
FAQ
The key risks are: 1) Clinical Failure Risk: The entire investment hinges on positive Phase 3 trial results for a single drug; failure would likely erase most of the stock's value. 2) Financial Risk: The company is burning over $130M in cash annually with no product revenue, necessitating future dilutive stock offerings. 3) Valuation Risk: The astronomical PS ratio of 794x leaves the stock vulnerable to severe multiple compression on any negative news. 4) Competitive & Regulatory Risk: Successful competitors or regulatory hurdles could diminish market potential. The clinical failure risk is the most severe, as it is binary and imminent.
The 12-month forecast for CGON is a wide range of outcomes centered on clinical trial results. The base case (50% probability) sees the stock trading between $50 and $75 as it consolidates ahead of data. The bull case (25% probability), driven by positive Phase 3 data, could propel the stock to $75-$110+. The bear case (25% probability), triggered by clinical failure, could see a collapse to the $23.65-$45 range, re-testing the 52-week low. The most likely scenario is the base case of volatile sideways action, but the expected value is skewed by the high-impact, low-probability nature of the binary event.
CGON is profoundly overvalued by any standard financial metric. With a Price-to-Sales ratio of 794.47x and negative earnings, the valuation is not based on current fundamentals but entirely on the future potential of its unapproved drug, cretostimogene. Compared to profitable companies or even most clinical-stage biotechs, this is an extreme premium. The market is pricing in near-perfect clinical success and blockbuster sales averaging $1.5 billion. Therefore, it is fairly valued only if one believes those future sales are highly probable; otherwise, it is dramatically overvalued.
CGON is a speculative buy only for investors with a very high risk tolerance and a long-term horizon who are comfortable with binary outcomes. The stock is not a 'good buy' in the traditional sense, as it lacks revenues, profits, and trades at an extreme valuation (PS ratio of 794x). However, the unanimous bullish analyst sentiment and strong balance sheet provide a framework for a high-risk bet on its lead drug's success. For most investors, it is not suitable; for specialized biotech investors, it could be a small, high-conviction position within a diversified portfolio, acknowledging the potential for total loss.
CGON is unsuitable for short-term trading due to its binary, news-driven nature and low beta (0.308) that masks event-specific volatility. It is a long-term, event-driven speculation with a horizon defined by clinical milestones. Investors should have a minimum holding period of 12-24 months to see through the upcoming Phase 3 data readouts and potential regulatory filing. There is no dividend, and earnings visibility is zero, making it purely a capital appreciation bet on a specific catalyst. It is not a 'set and forget' long-term investment but a tactical holding for those monitoring clinical developments closely.